Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2019 3
2020 11
2021 16
2022 18
2023 21
2024 17
2025 24
2026 37

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Göger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullén A; KEYNOTE-905/EV-303 Investigators. Vulsteke C, et al. N Engl J Med. 2026 Apr 2;394(13):1257-1269. doi: 10.1056/NEJMoa2511674. Epub 2026 Feb 18. N Engl J Med. 2026. PMID: 41707170 Clinical Trial.
BACKGROUND: Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. ...CONCLUSIONS: Perioperative enfortumab vedotin plus pembr …
BACKGROUND: Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy pro …
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Galsky MD, et al. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19. Future Oncol. 2021. PMID: 34008425 Free article.
Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis despite aggressive treatment. ...The randomized Phase III KEYNOTE-866 and KEYNOTE-905/EV-303 studies are being conducted to evaluate efficacy and safet …
Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis despite agg …
Top advances of the year: Bladder cancer.
Apolo AB, Atiq S, Kydd AR, Chelluri R, Millan B, Gurram S, Chandran E, Simon N. Apolo AB, et al. Cancer. 2025 Aug 15;131(16):e70020. doi: 10.1002/cncr.70020. Cancer. 2025. PMID: 40782344 Review.
Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) novel drug-delivery mechanisms in intravesical therapy for nonmuscle-invasive bladder cancer and muscle-invasive …
Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) …
Immunotherapy for esophageal cancer: Where are we now and where can we go.
Shoji Y, Koyanagi K, Kanamori K, Tajima K, Ogimi M, Ninomiya Y, Yamamoto M, Kazuno A, Nabeshima K, Nishi T, Mori M. Shoji Y, et al. World J Gastroenterol. 2024 May 21;30(19):2496-2501. doi: 10.3748/wjg.v30.i19.2496. World J Gastroenterol. 2024. PMID: 38817664 Free PMC article. Review.
Immune checkpoint inhibitor therapy has dramatically improved patient prognosis, and thereby transformed the treatment in various cancer types including esophageal squamous cell carcinoma (ESCC) in the past decade. Monoclonal antibodies that selectively inhib …
Immune checkpoint inhibitor therapy has dramatically improved patient prognosis, and thereby transformed the treatment …
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. Shah MA, et al. Future Oncol. 2021 Apr;17(10):1143-1153. doi: 10.2217/fon-2020-0969. Epub 2021 Feb 3. Future Oncol. 2021. PMID: 33533655 Free PMC article.
Combining pembrolizumab with chemoradiotherapy may further improve outcomes in the first-line setting. ...Overall survival and event-free survival are the dual primary end points. Clinical trial registration: NCT04210115 (ClinicalTrials.gov)....
Combining pembrolizumab with chemoradiotherapy may further improve outcomes in the first-line setting. ...Overall survival and …
CREST: phase III study of sasanlimab and Bacillus Calmette-Guerin for patients with Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer.
Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. Steinberg GD, et al. Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8. Future Oncol. 2024. PMID: 38189180 Free article.
Bacillus Calmette-Guerin (BCG) is the standard of care for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). ...The target sample size is around 1000 participants. Non-muscle …
Bacillus Calmette-Guerin (BCG) is the standard of care for patients with high-risk non-muscle-invasive bladder cance …
Immuno-oncology for esophageal cancer.
Yamamoto S, Kato K. Yamamoto S, et al. Future Oncol. 2020 Nov;16(32):2673-2681. doi: 10.2217/fon-2020-0545. Epub 2020 Aug 11. Future Oncol. 2020. PMID: 32777942 Free article.
Esophageal cancer (EC) is the seventh most common cancer, with a poor prognosis for metastatic EC patients and limited effective drugs for treatment. ...The KEYNOTE-181 trial that compared pembrolizumab with chemotherapy demonstrated superior OS for EC with a …
Esophageal cancer (EC) is the seventh most common cancer, with a poor prognosis for metastatic EC patients and limited effecti …
Guidelines of Onkopedia: What Is New?
Scheck MK, Al-Batran SE, Borner M, Gockel I, Götze TO, Grenacher L, Hass HG, Köberle D, Moehler M, Porschen R, Pritzkuleit R, Rumpold H, Sinn M, Stuschke M, Thuss-Patience P, Maschmeyer G, Wörmann B, Lorenzen S. Scheck MK, et al. Oncol Res Treat. 2025;48(10):655-662. doi: 10.1159/000546550. Epub 2025 May 30. Oncol Res Treat. 2025. PMID: 40451170 Free article.
This article presents new relevant aspects of the recently updated German, Swiss, Austrian Onkopedia guideline for the treatment of esophageal cancer. The full guideline can be accessed at <ext-link ext-link-type="uri" xlink:href="https://www.onkopedia-guidelines …
This article presents new relevant aspects of the recently updated German, Swiss, Austrian Onkopedia guideline for the treatment of esoph …
Advancements and challenges in the treatment of esophageal cancer: A comprehensive review.
Christodoulidis G, Agko SE, Koumarelas KE, Kouliou MN, Zacharoulis D. Christodoulidis G, et al. World J Clin Oncol. 2024 Dec 24;15(12):1463-1467. doi: 10.5306/wjco.v15.i12.1463. World J Clin Oncol. 2024. PMID: 39720647 Free PMC article.
Esophageal cancer (EC) is an aggressive malignancy with a poor prognosis, ranking seventh in incidence and sixth cancer-related deaths globally. ...Early-stage EC is often difficult to detect, leading to late-stage diagnoses that necessitate systemic drug therapies, …
Esophageal cancer (EC) is an aggressive malignancy with a poor prognosis, ranking seventh in incidence and sixth cancer-relate …
Immune checkpoint inhibitors for urothelial carcinoma.
Kim HS, Seo HK. Kim HS, et al. Investig Clin Urol. 2018 Sep;59(5):285-296. doi: 10.4111/icu.2018.59.5.285. Epub 2018 Aug 31. Investig Clin Urol. 2018. PMID: 30182073 Free PMC article. Review.
Currently, platinum-based cytotoxic chemotherapy is the standard treatment for metastatic UC (mUC) and the preferred treatment option in the perioperative (neoadjuvant and/or adjuvant) setting of muscle invasive bladder cancer (MIBC). In additio …
Currently, platinum-based cytotoxic chemotherapy is the standard treatment for metastatic UC (mUC) and the preferred treatment option in the …
139 results